Amyloids are the substance made up of abnormally formed protein in the bone marrow that gets saturated in different tissues or organs of the body. The condition is termed as amyloidosis. There are various types of amyloidosis out of which primary systemic amyloidosis are most common, these are associated with plasma cell dyscrasia and has no historical evidence of disease. Kidney, intestines, liver, heart and nerves are the common organs where amyloids get deposited and result in various localized complications. Deposition of amyloids in the heart causes continuous progression towards heart failure by cardiomyopathy, accumulation of amyloids renal system causes renal dysfunction and hepatomegaly can happen because of amyloids infiltration in the liver. Generally diagnosis of this disease is delayed because of no specific symptoms associated with it; however, some symptoms associated with disease include severe fatigue with weakness, feeling of satiety every time, difficulty in swallowing, swelling of tongue. There are several tests used for diagnosis of primary systemic amyloidosis depending on the organ affected, out of which Urinalysis, whole blood count, test for high creatinine level and liver function test are common.
Though primary systemic amyloidosis is very rare disease but it has spread across the world. According to article published by American Society of Nephrology (ASN), it is estimated that around five to twelve people per million per year are affected by primary systemic amyloidosis. At the same time, several numbers of cases of this disease remain undiagnosed. The scenario is similar in all regions of the world. All these facts represent significant demand of the various treatment options for primary systemic amyloidosis globally. The investment in research and development, suitable reimbursement conditions and advancements in diagnosis technologies may drive the growth of the market. On the other hand high cost involved in treatment and limited awareness may hinder the growth of the overall market. Currently there are many research projects under study that are focused on advancement in the treatment of primary systemic amyloidosis. Celgene Corporation in collaboration with Italian institute Fondazione I.R.C.C.S. – Policlinico San Matteo studying the use of of cyclophosphamide, lenalidomide and dexamethasone for previously treated patients with primary systemic amyloidosis, Boston University evaluating the safety and effect of doxycycline in patients with amyloidosis, French Nantes University Hospital studying the effect of lenalidomide in combination with melphalan and dexamethasone in newly-diagnosed patients, National Cancer Institute (NCI) in collaboration with Mayo Clinic using evaluating the use of lenalidomide, cyclophosphamide, and dexamethasone in treating patients with primary systemic amyloidosis.
Download exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2934
Primary systemic amyloidosis market can be segmented according to different categories such as regional geography and available treatment options. Geographically, this market can be segmented in four regions namely North American, Europe, Asia-Pacific and Rest of the World, out of all these segments North America region will have highest contribution in terms of value because of high awareness, higher percentage of total income spent on healthcare compared to other economies and appropriate reimbursement circumstances. Followed by this, Europe, Asia-Pacific and Rest of the World respectively could be major segments of the market. The market can also be segmented according to treatment options such as enzyme inhibitors, immune modulators, diuretics and others. The market can be divided according to symptomatic therapies.
Currently many established players in pharmaceuticals and biotechnology market catering varied range of products in this market. Out of these companies, Prothena Corporation plc, Celgene Corporation and Onclave Therapeutics Limited Llc are leading contributors.
Transparency Market Research
90 State Street,
NY – 12207
USA – Canada Toll Free 866-552-3453